Filing Flows › Travere Therapeutics (TVTX) › Q1 2025
Travere Therapeutics (TVTX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Travere Therapeutics (TVTX) reported revenue of $81.7M for the first quarter 2025 (Q1 2025), +98% from a year earlier and +9% from the quarter before. Operating margin was -52.2%, net loss $41.2M (50.4% of revenue).
Travere Therapeutics, Q1 2025: revenue $81.7M (+98% year over year), operating margin -52.2%, net loss $41.2M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $81.7M | +9% | +98% |
| Operating profit | −$42.7M | — | — |
| Net earnings | −$41.2M | — | — |
| Operating cash flow | −$42.2M | — | — |
What changed
Revenue was $81.7M in Q1 2025, up 98% year over year and up 9% from the previous quarter. FILSPARI was the largest line at 68% of revenue. FILSPARI added $36.0M year over year (up 182%), 89% of the total change. Tiopronin products declined 1%.
Operating costs exceeded revenue by $42.7M, an operating margin of -52.2%. Total costs fell 31% while revenue rose 98%. The fastest-growing cost line was Cost of revenue (+211%). The quarter ended with a net loss of $41.2M, narrower than the previous quarter's $60.3M loss.
Operating cash flow was −$42.2M. Non-cash charges added back $12.8M of depreciation and amortization and $11.5M of share-based compensation. Working capital and other items used $25.3M.
Questions
What was Travere Therapeutics' revenue in the first quarter 2025?
Travere Therapeutics (TVTX) reported revenue of $81.7M for the first quarter 2025 (Q1 2025), +98% from a year earlier and +9% from the quarter before.
Was Travere Therapeutics profitable in the first quarter 2025?
Operating loss was $42.7M (-52.2% of revenue) and net loss $41.2M.